, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

 to bring you a curated list of resources to use as you study for the hematology and oncology board exams. Drs Armstrong and Tawagi discussed their personal board review plans they followed in the months leading up to boards, including the books, sections of the National Comprehensive Cancer Network Guidelines, videos, question banks, and podcasts; where you can find the “cheat sheets” they made to help them study; and the importance of personalizing your study plan based on your own knowledge and strengths.

Podcasts

Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams. 

Board Review Resources 2024

 to bring you a review session for the oncology board exams. Drs Armstrong and Tawagi discussed high-yield oncology and hematology topics to focus on during study sessions, memorization tricks they used for their own boards, and other tips for exam preparation.

Drs Armstrong and Tawagi discuss high-yield oncology and hematology topics to focus on when studying for the 2024 oncology board exams. 

Heme & Onc Fellow Board Review Tips 2024

 to bring you insights on the phase 3 NADINA trial (NCT04949113), findings from which were presented at the 

 by Christian U. Blank, MD, PhD, of The Netherlands Cancer Institute in Amsterdam. NADINA evaluated neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) vs adjuvant nivolumab in patients with macroscopic, resectable, stage III melanoma. In this episode, Drs Armstrong and Tawagi discussed the staging and prior standard of care for locally advanced melanoma; key findings from NADINA; and how these data may impact clinical practice.

Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.

ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma

 to bring you insights on the phase 3 ADRIATIC trial (NCT03703297), which investigated durvalumab (Imfinzi) with or without tremelimumab (Imjudo) vs placebo as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not progressed following concurrent chemoradiotherapy. The findings from the durvalumab monotherapy and placebo arms of this trial were presented at the 

 by David R. Spigel, MD, of Sarah Cannon Research Institute in Nashville, Tennessee. In this episode, Drs Armstrong and Tawagi reviewed common risk factors, pathology, presentation, and staging of SCLC; the current standard of care for patients with LS-SCLC; and key findings from ADRIATIC that inspired a standing ovation at ASCO.

OncLive On Air partners with Two Onc Docs to bring insights on the ADRIATIC trial, data from which were presented at the 2024 ASCO Annual Meeting.

ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer

, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. 

 to bring you insights on the primary results of the 

 (NCT03521154), which were presented at the 

 by Suresh S. Ramalingam, MD, FACP, FASCO, of the Winship Cancer Institute of Emory University in Atlanta, Georgia. LAURA evaluated osimertinib following chemoradiation in patients with stage III, unresectable, 

-mutated non–small cell lung cancer (NSCLC). Drs Armstrong and Tawagi shared lung cancer staging tips; explained standard treatment strategies for stage I, II, and IIIA NSCLC; highlighted key findings from LAURA; and discussed questions raised by the trial’s design and its findings.

OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.

Karine Tawagi, MD

Articles

Board Review Resources 2024

Heme & Onc Fellow Board Review Tips 2024

ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma

ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer

ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC